Search Results for:
-
Other News To Note
In order to accomplish that, the company will reduce its overall cost structure, particularly in early stage programsBioWorld International | Wednesday, February 13, 2013 -
Partnering Your Way to M&A? Keep Cash Balance, Options
After reaching a certain point in development, Biogen decided it wanted those compounds back and acquired Stromedix in a $562.5 million deal, said Michael Gilman, who headed up Stromedix and now serves as senior vice president of early stage research at BiogenBy Jennifer Boggs | BioWorld Today | Wednesday, February 13, 2013 -
e-Therapeutics Raises $63M to Fund Solid Tumor Drug
Obviously we've got money so any deal would have to be good, but we would consider early stage deals if they were lucrative enough," Young said.By Nuala Moran | BioWorld International | Wednesday, February 13, 2013 -
e-Therapeutics Raises $63M to Fund Solid Tumor Drug
Obviously we've got money so any deal would have to be good, but we would consider early stage deals if they were lucrative enough," Young saidBy Nuala Moran | BioWorld Today | Tuesday, February 12, 2013 -
Partner, NIH: Other Chances for Ampligen CFS Campaign?
Within its National Center for Accelerating Translational Sciences, the NIH has established the Therapeutics for Rare and Neglected Diseases program, "established with this sort of situation in mind, although I think it was geared toward the earlier stage of clinical research, and not waiting until you're in Phase III," McCleary saidBy Randy Osborne | BioWorld Today | Monday, February 11, 2013 -
Final Rule is in Place, but the Sun Isn't Shining Yet
That timeline was tossed out the window due to CMS' 15-month delay in finalizing the rule. (See BioWorld Today, Oct. 5, 2011, and Jan. 24, 2013.) FDA Wants Input The FDA is seeking comment on draft guidances released last week on immunogenicity assessment of therapeutic protein products and the development of drugs to treat early stage Alzheimer's...Intended as a conversation starter, the other draft guidance addresses the clinical development of drugs to treat early stages of Alzheimer's diseaseBy Mari Serebrov | BioWorld Today | Monday, February 11, 2013 -
Celgene Hat Trick: Pomalyst Joins Multiple Myeloma Arsenal
In addition to solidifying its MM presence with Pomalyst, Celgene is placing bets on early stage contendersBy Marie Powers | BioWorld Today | Monday, February 11, 2013 -
Pharmas Confront Another Pipeline Problem: Talent Drain
With much of the early stage discovery and development effort now delegated to third parties, "the skill sets needed are for people who can oversee and manage" these projects, Franco said. (See graph, The life sciences industry is looking for new skills among scientists.) Biopharmas "need people who have a broader perspective," so they understand how each piece of data flows together "to tell a complete story," Franco explainedBy Marie Powers | BioWorld Today | Friday, February 8, 2013 -
Other News To Note
In order to accomplish that, the company will reduce its overall cost structure, particularly in early stage programsBioWorld Today | Friday, February 8, 2013 -
Celldex Seeks $90M, End Zone for Rindopepimut
Celldex largely eschewed early stage partnerships after it was spurned by New York-based Pfizer Inc...The company also has earlier-stage assets that could add value in the coming years, including the monoclonal antibody vaccine CDX-1401 targeting solid tumors, CD27-targeting candidate CDX-1127 and CDX-301, a recombinant human FMS-like tyrosine kinase 3 ligandBy Marie Powers | BioWorld Today | Thursday, February 7, 2013 -
Let 'EdRIP': VC Fund Seeks $677M for Life Science Firms
The overall approach allows the firm to "take account of liquidity requests" but also to capture the potential for higher returns from earlier-stage, riskier ventures...it can be difficult to finance early stage, and you need to do a decent job to raise the next round," Litzka saidBy Nuala Moran | BioWorld International | Wednesday, February 6, 2013 -
Pharma: Other News To Note
Janssen Research & Development LLC, of Titusville, N.J., a unit of Johnson & Johnson, said its San Diego-based Janssen Labs added a Concept Lab, a shared laboratory to offer entrepreneurs access to bench spaces for early stage research, and an Open Collaboration Space, an open-plan office setting designed to provide companies and individuals with desk spaceBioWorld Today | Wednesday, February 6, 2013 -
Research Alliance Seeks to Accelerate Drug Development
Similarly, CDRC provides expertise and infrastructure to researchers at Canada's leading health research institutions so they can advance promising early stage drug candidates, de-risk them and transform them into viable investment opportunities for the private sector...The centers recognize that they won't rescue every early stage therapeutic programBy Marie Powers | BioWorld Today | Monday, February 4, 2013 -
Word on the Street
He and his colleagues have created a mouse with a reporter gene that appears to light up at the earliest stages of tumor development, regardless of the tissue type in which the tumor is developing "We said all along that Zerenex was the only phosphate binder that had the potential to transcend into another dialysis category – in this case, anemia management – and generate some benefit." – Ron Bentsur, CEO, Keryx Biopharmaceuticals IncBioWorld Insight | Monday, February 4, 2013 -
Drug Discovery Alliance Aims To Boost Translational Hit Rate
Many are allied with other research institutions to advance early stage drug candidates and provide gap funding...Es Sabar hopes the work of the alliance will strengthen early stage biopharma licensing deals and create stronger, more sustainable biotechsBy Marie Powers | BioWorld Insight | Monday, February 4, 2013 -
Clinic Roundup
Ceptaris Therapeutics Inc., of Malvern, Pa., said results of a pivotal trial comparing its gel formulation of mechlorethamine hydrochloride 0.02 percent to pharmacy-compounded mechlorethamine ointment for the treatment of early stage mycosis fundoides were published in JAMA DermatologyBioWorld Today | Thursday, January 31, 2013 -
Clinic Roundup
Early stage data are expected late this yearBioWorld Today | Wednesday, January 30, 2013 -
Cytox Raises $5.5M to Continue Alzheimer's Test Development
That would both provide an advance in terms of the care of people with the disease and in enabling drugs to be tested in the earlier stages of the disease when there is a greater likelihood of showing a significant clinical effect...If they are, we need to get them to patients at an earlier stage of diseaseBy Nuala Moran | BioWorld International | Wednesday, January 30, 2013 -
Biomarker of Aging Renders Early Stage Cancers Visible
By Anette Breindl Science Editor Researchers have created a mouse with a reporter gene that appears to light up at the earliest stages of tumor development, regardless of the tissue type in which the tumor is developing...It really does seem to work in every malignancy we've tested," Norman Sharpless told BioWorld Today, which makes the mouse in question a broadly useful tool to study the earliest stages of tumor developmentBio Perspectives | Tuesday, January 29, 2013 -
Biogen Misses EPS, Exceeds Revenue; BG-12 Launch Next
In addition to late-stage advancements, Biogen also inked several early stage deals in 2012, including a microRNA agreement with Regulus Therapeutics IncBy Jennifer Boggs | BioWorld Today | Tuesday, January 29, 2013
Category
Current Filters
- xearly stage
Related Keywords
Categories
- x BioWorld Today (2903)
- x BioWorld International (822)
- x BioWorld Insight (440)
- x Bio Perspectives (175)
- x State of the Industry Report (78)
- x BioWorld Genomics Review (24)
- x BioWorld Snapshots (21)
- x Biotech Innovations (19)
- x Top 25 Drug Report (11)
- x Market-Leading Biotech Drugs (3)
- x BioWorld Phase III Report (1)
- x RNAi Report (1)
- x MDD (1)
- x Recorded (1)
BioWorld | 3525 Piedmont Road
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Building 6, Suite 400 | Atlanta, Georgia 30305, USA
Part of Thompson Media Group LLC
Free Ezine
Sign up for Perspectives FREE e-mail newsletter.
Customer Service: In the U.S. and Canada: 1-800-477-6307
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Outside the U.S.: 1-404-262-5423
customerservice@bioworld.com
Hours: Monday - Thursday, 8:30 am - 6:00 pm EST
Friday, 8:30am - 4:30 pm EST
Copyright @ 2013 AHC Media. Reproduction, reposting content is strictly prohibited.